Regeneron Pharmaceuticals Inc logo

Regeneron Pharmaceuticals Inc (RGO)

Market Open
31 Mar, 20:00
580. 60
-14.4
-2.42%
- Market Cap
24.52 P/E Ratio
0% Div Yield
126 Volume
42.79 Eps
595
Previous Close
Day Range
572 590.4
Year Range
572 1,088
Earnings results expected in 28 days

Summary

RGO trading today lower at €580.6, a decrease of 2.42% from yesterday's close, completing a monthly decrease of -13.24% or €88.6. Over the past 12 months, RGO stock lost -15.19%.
RGO pays dividends to its shareholders, with the most recent payment made on Aug 26, 2022.
The last earnings report, released on Jan 31, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Apr 30, 2025.
The stock of the company had never split.
The company's stock is traded on 13 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track RGO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

RGO Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.

Regeneron Pharmaceuticals Inc Dividends

Regeneron Pharmaceuticals Inc logo
RGO 11 Aug 2022
Estimated
Other
€0 Per Share
Regeneron Pharmaceuticals Inc logo
RGO 11 Aug 2022
Paid
Other
€0 Per Share
Regeneron Pharmaceuticals Inc logo
RGO 15 Jul 2021
Paid
Other
€0 Per Share

Regeneron Pharmaceuticals Inc Earnings

30 Apr 2025 (28 Days) Date
-
Cons. EPS
-
EPS
31 Jan 2025 Date
-
Cons. EPS
-
EPS
31 Oct 2024 Date
-
Cons. EPS
-
EPS
1 Aug 2024 Date
-
Cons. EPS
-
EPS
14 May 2024 Date
-
Cons. EPS
-
EPS
Regeneron Pharmaceuticals Inc logo
RGO 11 Aug 2022
Estimated
Other
€0 Per Share
Regeneron Pharmaceuticals Inc logo
RGO 11 Aug 2022
Paid
Other
€0 Per Share
Regeneron Pharmaceuticals Inc logo
RGO 15 Jul 2021
Paid
Other
€0 Per Share
30 Apr 2025 (28 Days) Date
-
Cons. EPS
-
EPS
31 Jan 2025 Date
-
Cons. EPS
-
EPS
31 Oct 2024 Date
-
Cons. EPS
-
EPS
1 Aug 2024 Date
-
Cons. EPS
-
EPS
14 May 2024 Date
-
Cons. EPS
-
EPS

Regeneron Pharmaceuticals Inc (RGO) FAQ

What is the stock price today?

The current price is €580.60.

On which exchange is it traded?

Regeneron Pharmaceuticals Inc is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is RGO.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on Apr 30, 2025.

Has Regeneron Pharmaceuticals Inc ever had a stock split?

No, there has never been a stock split.

Regeneron Pharmaceuticals Inc Profile

Biotechnology Industry
Healthcare Sector
Dr. Leonard S. Schleifer M.D., Ph.D. CEO
XFRA Exchange
US75886F1075 ISIN
US Country
13,450 Employees
- Last Dividend
- Last Split
2 Apr 1991 IPO Date

Overview

Regeneron Pharmaceuticals, Inc. is a biotechnology firm that is renowned for its dedication to discovering, inventing, developing, manufacturing, and commercializing medicines to combat a variety of diseases globally. Since its inception in 1988, the company has been at the forefront of innovative treatments, striving to address the unmet medical needs of patients around the world. With its headquarters nested in Tarrytown, New York, Regeneron has made a significant impact in the pharmaceutical industry by delivering life-changing medicines to patients in need.

Products and Services

Regeneron Pharmaceuticals, Inc. offers a diverse portfolio of products aimed at treating a wide range of diseases, including but not limited to, eye diseases, allergies and inflammations, cardiovascular and metabolic conditions, infectious diseases, rare diseases, cancers, pain, and hematologic conditions.

  • EYLEA Injection: Used for the treatment of wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
  • Dupixent Injection: Offers relief for adults and children suffering from atopic dermatitis and asthma, targeting the underlying inflammation and immune system response.
  • Libtayo Injection: Approved for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma, providing a much-needed option for patients with this serious skin cancer.
  • Praluent Injection: Aimed at adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, this medication works by reducing LDL cholesterol levels.
  • REGEN-COV: For patients with COVID-19, offering a treatment option to help reduce the severity of the disease and potential hospitalization.
  • Kevzara Solution: Designed for adults with rheumatoid arthritis, Kevzara works by interfering with the inflammatory pathway to reduce symptoms and slow disease progression.
  • Inmazeb Injection: The first FDA-approved treatment for infection caused by Zaire ebolavirus, offering hope to patients facing this deadly disease.
  • ARCALYST Injection: Treats cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome, by targeting the body’s inflammatory response.
  • ZALTRAP Injection: Used in combination with chemotherapy for the treatment of metastatic colorectal cancer, aiming to slow the spread of the disease.

In addition to these products, Regeneron is continuously working on developing new treatments for a variety of diseases, demonstrating their commitment to innovation and improving patient health worldwide.

Contact Information

Address: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Phone: 914 847 7000